IRIS
ARCAINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.226
AS - Asia 6.780
EU - Europa 4.867
SA - Sud America 907
AF - Africa 222
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 10
Totale 21.032
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.988
CN - Cina 2.832
SG - Singapore 1.608
IE - Irlanda 1.103
HK - Hong Kong 880
BR - Brasile 652
VN - Vietnam 652
RU - Federazione Russa 595
IT - Italia 507
DE - Germania 506
FI - Finlandia 494
FR - Francia 476
UA - Ucraina 424
GB - Regno Unito 259
SE - Svezia 225
IN - India 201
CA - Canada 118
ZA - Sudafrica 112
AR - Argentina 97
BD - Bangladesh 83
JP - Giappone 74
MX - Messico 68
IQ - Iraq 61
TR - Turchia 61
ID - Indonesia 50
PL - Polonia 47
NL - Olanda 45
PK - Pakistan 39
CO - Colombia 35
BE - Belgio 32
EC - Ecuador 31
ES - Italia 31
MA - Marocco 27
SA - Arabia Saudita 27
VE - Venezuela 26
AT - Austria 21
AU - Australia 19
JO - Giordania 19
UZ - Uzbekistan 19
MY - Malesia 18
PH - Filippine 18
CL - Cile 16
LT - Lituania 16
TN - Tunisia 16
IR - Iran 15
KE - Kenya 15
PY - Paraguay 15
JM - Giamaica 14
AE - Emirati Arabi Uniti 13
CZ - Repubblica Ceca 13
BO - Bolivia 12
AZ - Azerbaigian 11
KR - Corea 11
PE - Perù 10
EG - Egitto 9
IL - Israele 9
DO - Repubblica Dominicana 8
EU - Europa 8
KZ - Kazakistan 8
MD - Moldavia 8
PA - Panama 8
RO - Romania 8
UY - Uruguay 8
DZ - Algeria 7
GR - Grecia 7
KG - Kirghizistan 7
LB - Libano 7
NP - Nepal 7
BA - Bosnia-Erzegovina 6
CH - Svizzera 6
ET - Etiopia 6
OM - Oman 6
PS - Palestinian Territory 6
SN - Senegal 6
AL - Albania 5
CY - Cipro 5
DK - Danimarca 5
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
SY - Repubblica araba siriana 5
TH - Thailandia 5
BH - Bahrain 4
CI - Costa d'Avorio 4
CU - Cuba 4
GY - Guiana 4
QA - Qatar 4
HU - Ungheria 3
KW - Kuwait 3
NG - Nigeria 3
NI - Nicaragua 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
BS - Bahamas 2
BY - Bielorussia 2
CG - Congo 2
EE - Estonia 2
GE - Georgia 2
Totale 20.990
Salva come PNG Salva come JPEG
Città #
Dublin 1.100
Chandler 1.019
Singapore 893
Hong Kong 864
San Jose 827
Ashburn 746
Dallas 684
Jacksonville 577
Nanjing 523
Beijing 521
Boardman 357
Los Angeles 254
Lauterbourg 241
Princeton 220
Ho Chi Minh City 214
Lawrence 202
Nanchang 201
New York 185
Wilmington 184
Hebei 172
Hanoi 158
Helsinki 157
Changsha 144
Medford 143
Shenyang 140
Munich 132
Ann Arbor 130
Jiaxing 124
Shanghai 110
Buffalo 107
Tianjin 106
Redondo Beach 103
Moscow 101
Johannesburg 90
Hangzhou 79
Santa Clara 74
Milan 73
São Paulo 72
Pavia 70
Tokyo 66
Seattle 52
Turku 52
Orem 49
The Dalles 46
Pune 45
Chennai 43
Falkenstein 42
Frankfurt am Main 41
San Francisco 41
Columbus 37
Montreal 36
Stockholm 36
Warsaw 36
Woodbridge 36
Falls Church 35
Da Nang 33
Norwalk 33
Toronto 33
Nuremberg 31
Brussels 30
Chicago 30
Brooklyn 27
Guangzhou 25
Washington 25
Mexico City 24
Baghdad 23
London 23
Manchester 23
Paris 23
Ankara 22
Verona 22
Haiphong 21
Poplar 21
Belo Horizonte 20
Zhengzhou 20
Atlanta 19
Denver 19
Houston 19
Rome 18
Amsterdam 17
Council Bluffs 16
Fairfield 16
Tashkent 16
Amman 15
Des Moines 15
Dhaka 15
Boston 14
Brescia 13
Istanbul 13
Jakarta 13
Phoenix 13
Brasília 12
Hải Dương 12
Jinan 12
Xi'an 12
Bến Tre 11
Kingston 11
New Delhi 11
Auburn Hills 10
Buenos Aires 10
Totale 13.651
Salva come PNG Salva come JPEG
Nome #
Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study 190
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 185
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 178
Absence of MYD88 L265P mutation in blastic plasmacytoid dendritic cell neoplasm 166
An insidious presentation of splenic marginal zone lymphoma 157
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 155
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma 149
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution 143
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 142
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma 142
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 141
Depletion of circulating IgM memory B cells predicts unfavourable outcome in COVID-19 138
Blast phase of essential thrombocythemia: A single center study. 137
FLIPI2: A New Prognostic Index For Follicular Lymphoma Developed By The International Follicular Lymphoma Prognostic Factor Project (IFLPFP) 136
Antibiotic therapy-induced remission of bladder mucosa-associated lymphoid tissue (MALT) lymphoma carrying t(11;18)(q21;q21) apoptosis inhibitor 2-MALT1. 136
Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk 135
Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. 130
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 127
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 126
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 126
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 125
CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case 124
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 124
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders 124
Splenic nodal and extranodal marginal zone lymphoma: features of bone marrow involvement. 123
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma 123
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 120
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers 120
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 119
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients 115
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 115
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection 115
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 113
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 113
A young woman with microcytic anemia and hypertransaminasemia 113
Clinical and Histopathological Features of an Italian Monocentric Series of Primary Small Bowel T-Cell Lymphomas 111
Risk stratification for splenic marginal zone lymphoma based on hemoglobin, platelet count, high LDH level and extrahilar lymphadenopathy: development and validation on 593 cases 110
Everolimus in diffuse large B-cell lymphomas 110
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 110
Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice 109
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 107
Antiviral therapies for managing viral hepatitis in lymphoma patients 106
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 106
A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. 106
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis 105
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 105
Diagnosis and management of prefibrotic myelofibrosis. 105
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 104
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. 104
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network 104
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network 104
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 103
Case Report: A rare case of small bowel obstruction secondary to plasma cell myeloma 102
ICA-EMA: A Tool for Assessing Nursing Complexity of Patients With Oncohematologic Disease in an Italian Center 102
A paraumbilical lymphomatous mass 101
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction 101
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 100
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 100
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 100
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience 99
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 99
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 98
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 98
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 98
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 96
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. 95
Regression of indolent B-cell lymphoma after Lamivudine prophylaxis of hepatitis B virus infection. 95
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 95
Transient response of myeloma clone to pamidronate therapy 94
MYD88 L265P somatic mutation in Waldenstrom’s Macroglobulinemia 94
Retrospective Investigation of Human Papillomavirus Cervical Infection and Lymphoma Incidence: A Clinical and Pathological Evaluation 92
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 92
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 92
Role of the molecular staging and response in the management of follicular lymphoma patients 92
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy 92
Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy 92
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 92
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 91
R-CVP vs R-CHOP vs R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi (FIL) 91
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 91
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins 91
The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 91
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 90
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 90
Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms 89
Mantle cell lymphoma of mucosa-associated lymphoid tissue: A european mantle cell lymphoma network study 89
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders 89
Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. 88
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia 88
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 87
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 87
The NOTCH pathway is recurrently mutated in diffuse large B cell lymphoma associated with hepatitis C virus infection. 87
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial 87
Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease 86
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). 86
Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features. 86
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. 86
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 86
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 85
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 85
Totale 10.971
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.869
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.869
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021263 0 0 0 0 0 0 0 0 0 123 115 25
2021/2022971 22 5 19 15 38 55 19 56 53 40 141 508
2022/20232.990 277 196 21 239 279 318 27 177 1.257 28 111 60
2023/20241.404 147 234 60 97 107 395 34 84 12 53 74 107
2024/20253.794 116 269 74 88 78 233 349 242 846 136 466 897
2025/20268.124 637 663 1.000 1.009 956 351 1.818 325 798 567 0 0
Totale 21.649